Bacci G, Ferrari S, Bertoni F, Picci P, Bacchini P, Longhi A, Donati D, Forni C, Campanacci L, Campanacci M
Service of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy.
Clin Orthop Relat Res. 2001 May(386):186-96. doi: 10.1097/00003086-200105000-00024.
In 510 patients with osteosarcoma of the extremity treated at the authors' institute between March 1983 and June 1995 with different regimens of neoadjuvant chemotherapy, factors that influenced the histologic response were investigated. The rate of total necrosis was not related to the patients' gender, age, site, size of tumor, serum of alkaline phosphatase values, or route of cisplatin administration. The histologic response significantly and independently correlated with the number of drugs administered before surgery and with the histologic subtype of the tumor. According to the number of drugs used, the percentage of total necrosis was 31% for a four-drug regimen, 18% for a three-drug regimen, and only 1.5% for a two-drug regimen. According to the histologic type, the rates of total necrosis were 41% for telangiectatic tumors, 36% for fibroblastic tumors, 15% for osteoblastic tumors, and 3% for chondroblastic tumors. The authors concluded that in neoadjuvant therapy of osteosarcoma, the histologic response to preoperative treatment, which correlates with prognosis, depends on the effectiveness of the chemotherapy regimen and on some features intrinsically inherent to the tumor. These data should be considered when selecting the type of treatment (adjuvant or neoadjuvant) and the combinations of drugs to be used in preoperative treatment of patients with osteosarcoma.
1983年3月至1995年6月期间,作者所在机构采用不同新辅助化疗方案治疗了510例肢体骨肉瘤患者,对影响组织学反应的因素进行了研究。肿瘤总坏死率与患者的性别、年龄、部位、肿瘤大小、血清碱性磷酸酶值或顺铂给药途径无关。组织学反应与术前给药的药物数量及肿瘤的组织学亚型显著且独立相关。根据用药数量,四联化疗方案的肿瘤总坏死率为31%,三联化疗方案为18%,二联化疗方案仅为1.5%。根据组织学类型,血管扩张型肿瘤的总坏死率为41%,纤维母细胞型肿瘤为36%,成骨细胞型肿瘤为15%,软骨母细胞型肿瘤为3%。作者得出结论,在骨肉瘤的新辅助治疗中,术前治疗的组织学反应与预后相关,取决于化疗方案的有效性及肿瘤本身的一些固有特征。在选择骨肉瘤患者的治疗类型(辅助或新辅助)及术前治疗所用药物组合时,应考虑这些数据。